As of Apr 28
| -0.03 / -0.34%|
The 8 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 12.00, with a high estimate of 14.00 and a low estimate of 8.00. The median estimate represents a +38.41% increase from the last price of 8.67.
The current consensus among 9 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.